Fast Five Quiz: KRAS Mutations in Non-Small Cell Lung Cancer

Winston W. Tan, MD; Maurie Markman, MD


August 16, 2022

Patients with KRAS mutations tend to have a poorer prognosis, and KRAS mutations have been identified as negative prognostic biomarkers. Patients with KRAS mutations appear to have a shorter survival than those with wild-type KRAS. However, KRAS mutational status is not predictive of a lack of chemotherapeutic efficacy, according to NCCN guidelines.

A 2018 meta-analysis indicated that EGFR mutations were significantly associated with improved OS and disease-free survival, whereas KRAS mutations predicted worse disease-free survival and OS in patients with resected NSCLC.

Learn more about the clinical significance of KRAS mutations in NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.